|
Real-time Estimate
Cboe BZX
15:15:11 2026-11-03 EST
|
5-day change | 1st Jan Change | ||
| 2.595 USD | +9.49% |
|
+8.58% | -31.89% |
| 09-29 | Larimar Therapeutics Names John Harlow COO | MT |
| 09-28 | Larimar Therapeutics, Inc. Announces Appointment of John Harlow as President and Chief Operating Officer, Effective September 29, 2026 | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 247M | - | - | - | - | - |
| 62.23B | |||||
| 54.92B | |||||
| 55.26B | |||||
| 42.59B | |||||
| 41.08B |
Select your edition
All financial news and data tailored to specific country editions
